Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9
科學論文
Consolidation Serplulimab Following Concurrent Hypofractionated Chemoradiotherapy for Limited-stage SCLC: Preliminary Analysis of Phase II ASTRUM-LC01 Study
ESMO 2024
"First-line serplulimab vs. placebo combined with chemotherapy for extensive-stage small-cell lung cancer: extended follow-up results and patient-reported outcomes for the Asian population from the international phase 3 ASTRUM-005 study"
CSCO 2024
"A phase 3 study of serplulimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer: ASTRUM-004 Chinese subgroup"
